Tibet Aim Pharm

Tibet Aim Pharm EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 33.33. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 34.60 — a change of -3.65% (lower).

EV/FCF

33.33

YoY

-3.65%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Aim Pharm is 2025 33.33 . EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Aim Pharm was 2024 34.60 . It decreases by -3.65% lower compared to the previous year.

The Tibet Aim Pharm EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-66.95 CNY
Jan 1, 2019
-33.45 CNY
Jan 1, 2020
58.06 CNY
Jan 1, 2021
43.46 CNY
Jan 1, 2022
54.70 CNY
Jan 1, 2023
21.17 CNY
Jan 1, 2024
34.60 CNY
Jan 1, 2025
33.33 CNY
The Tibet Aim Pharm EV/FCF history
YEAREV/FCFYoY
33.33-3.65%
34.60+63.39%
21.17-61.29%
54.70+25.87%
43.46-25.15%
58.06-273.59%
-33.45-50.04%
-66.95-105.00%
1,339.36+1,350.50%
92.34-276.57%
-52.30-41.09%
-88.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Aim Pharm is 33.33 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Aim Pharm changed from 34.60 to 33.33, representing a -3.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Tibet Aim Pharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm